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ABSTRACT 
Right ventricular (RV) function determines prognosis in pulmonary arterial hypertension 
(PAH). We hypothesize that ischemia causes RV dysfunction in PAH by triggering 
dynamin-related protein 1 (Drp1)-mediated mitochondrial fission. RV function was 
compared in control rats (n=50) versus rats with monocrotaline-induced PAH (MCT-
PAH; n=60) both in vivo (echocardiography) and ex vivo (RV Langendorff). 
Mitochondrial membrane potential and morphology and RV function were assessed 
before or after two cycles of ischemia-reperfusion injury challenge (RV-IR). The effects 
of Mdivi-1 (25 μM), a Drp1 GTPase inhibitor and P110 (1 μM), a peptide inhibitor of 
Drp1-Fis1 interaction were studied. We found that MCT caused RV hypertrophy, RV 
vascular rarefaction and RV dysfunction. Prior to IR, the mitochondria in MCT-PAH RV 
were depolarized and swollen with increased Drp1 content and reduced aconitase 
activity. RV-IR increased RV end diastolic pressure (RVEDP) and mitochondrial Drp1 
expression in both control and MCT-PAH RVs. IR depolarized mitochondria in control 
RV but did not exacerbate the basally depolarized MCT-PAH RV mitochondria. During 
RV IR mdivi-1 and P110 reduced Drp1 translocation to mitochondria, improved 
mitochondrial structure and function, and reduced RVEDP. In conclusion, RV ischemia 
occurs in PAH and causes Drp1-Fis1-mediated fission leading to diastolic dysfunction. 
Inhibition of mitochondrial fission preserves RV function in RV-IR. 
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Abbreviations: 
Albumin-FICT, albumin–fluorescein isothiocyanate conjugate 
CO, cardiac output 
DCA, dichloroacetate 
DMSO, dimethyl sulfoxide 
Drp1, dynamin-related protein 1 
EDP, end diastolic pressure 
Fis1, fission protein 1 
IR, ischemia-reperfusion 
KH, Krebs-Henseleit 
LV, left ventricle 
LV-IR, left ventricular ischemia reperfusion 
LV+S, left ventricle plus septum 
LVEDP, left ventricular end diastolic pressure 
MCT, monocrotaline 
Mdivi-1, mitochondrial division inhibitor 1 
MFF, mitochondrial fission factor 
OMM, outer mitochondrial membrane 
PAAT, pulmonary artery acceleration time 
PAH, pulmonary arterial hypertension 
PBS, phosphate buffered saline 
PDH, pyruvate dehydrogenase 
ROS, reactive oxygen species 
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RV, right ventricle 
RVEDP, right ventricular end diastolic pressure 
RVSP, right ventricular systolic pressure 
RVFW, right ventricular free wall 
RVH, right ventricular hypertrophy 
RV-IR, right ventricular ischemia reperfusion 
TAPSE, tricuspid annular plane systolic excursion 
TEM, transmission electron microscopy 
TMRM, tetramethylrhodamine methyl ester 
VDAC, anti-voltage-dependent anion channel 
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INTRODUCTION 
Right ventricular (RV) ischemia is a feature of pulmonary arterial hypertension (PAH), 
which contributes to RV failure. Evidence of RV ischemia in PAH patients includes 
abnormal coronary artery flow reserve [1] and elevated plasma troponin levels [2]. In 
PAH, RV ischemia can result from microvascular rarefaction [3,4], reduced epicardial 
coronary artery perfusion pressure [5,6], or both. In addition, PAH patients are exposed 
to periodic episodes of hypotension, arrhythmia and/or surgical procedures that may 
expose the RV to ischemia-reperfusion injury (IR) [7]. The effects of basal ischemia and 
IR on the RV in health and in PAH are unknown.   
 
In the left ventricle (LV), IR impairs systolic function indicated by reducing developed 
pressure and diastolic function indicated by elevating end diastolic pressure (EDP) [8,9]. 
In LV-IR, production of reactive oxygen species (ROS) and the resulting LV dysfunction 
largely result from fission of mitochondria in cardiac myocytes [10-13].  
 
Dynamin-related protein 1 (Drp1) normally resides in the cytosol, but upon activation, 
translocates to the mitochondria where it associates with binding partners located on the 
outer mitochondrial membrane (OMM), including fission protein 1 (Fis1), mitochondrial 
fission factor (MFF), and mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 and 
MiD51) [14-16]. Drp1 and its binding partners create a multimeric fission apparatus that 
constricts and divides the mitochondria (reviewed in [17]). Drp1 can be activated by 
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dephosphorylation of serine 637, as occurs in IR [10,11,18], or phosphorylation at serine 
616 [19,20].  
 
The small molecule, mitochondrial division inhibitor 1 (Mdivi-1), which is a Drp1 
GTPase inhibitor, preserves mitochondrial morphology in ischemic LV cardiac myocytes 
[10,12]. In global LV-IR, Mdivi-1 reduces ROS production, preserves mitochondrial 
morphology and improves pulse pressure development [10]. In vivo, Mdivi-1 ameliorates 
aortic banding-induced heart failure [21], reduces myocardial infarct size [12], and 
improves survival in a mouse cardiac arrest model [11]. Preventing the interaction 
between Drp1 and Fis1, using the disruptive peptide P110, also preserves mitochondrial 
morphology and myocyte function in neonatal rat cardiac myocytes [13].  
 
Here, we demonstrate that ischemia, whether occurring in vivo due to the vascular 
rarefaction that occurs in MCT-PAH or induced ex vivo in the RV Langendorff model, 
causes mitochondrial fission. Increased fission in RV myocytes from PAH RV causes RV 
diastolic dysfunction. Ischemia-induced fission involves Drp1 translocation to the 
mitochondria. Interaction of Drp1 and Fis1 mediate the resulting RV injury. RV function 
is preserved ex vivo by inhibiting ischemia-induced mitochondrial fission. This research 
has relevance for PAH, a condition in which RV function, determined in part by RV 
ischemia, is a major determinant of prognosis. 
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MATERIALS AND METHODS 
Experiments were conducted in accordance with published guidelines of the Canadian 
Council on Animal Care and approved by the Queen’s University Animal Care 
Committee.  
 
Reagents 
Monocrotaline (MCT), Mdivi-1, dimethyl sulfoxide (DMSO), Krebs-Henseleit (KH) 
buffer, sodium bicarbonate, calcium chloride dehydrate, heparin sodium salt and 
albumin–fluorescein isothiocyanate conjugate (albumin-FITC) were purchased from 
Sigma (St. Louis, MO, USA). The P110 peptide includes TAT to enhance membrane 
permeability. Both P110 and the peptide control sequence, TAT, were purchased from 
United Peptide (Herndon, VA, USA). Phosphate buffered saline (PBS) was purchased 
from Fisher Scientific (Fair Lawn, NJ, USA).   
 
Monocrotaline-induced PAH  
Experimental procedures were conducted on male Sprague-Dawley rats (Charles River, 
QC, Canada). Animals were initially pair-housed in a colony room (12/12 h light cycle; 
light off at 19:00) with ad libitum access to food and water. All experimental procedures 
took place between the time of 9:00 and 18:00. At the weight of ~ 250 g, rats received a 
single subcutaneous injection of MCT (60 mg/kg, SC) or PBS. 
 
Echocardiography 
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Doppler, 2-dimensional, and M-mode echocardiography was performed 6-24 hours prior 
to the RV Langendorff surgery, using a high-frequency ultrasound system (Vevo 2100; 
Visual Sonics, Toronto, ON, Canada), as described [22]. Pulmonary artery acceleration 
time (PAAT), pulmonary artery diameter at the level of the pulmonary outflow tract 
during mid-systole, diastolic and systolic thickness of the RV free wall (RVFW), and 
tricuspid annular plane systolic excursion (TAPSE) were measured. RVFW systolic 
thickening and cardiac output (CO) were calculated as described [22,23]. 
 
Treadmill distance 
Exercise capacity was evaluated 6-24 hours prior to the sacrifice of animals by measuring 
the maximal distance run on a motor-driven treadmill (Simplex II Instrument, Columbus 
Instruments; Columbus, OH, USA), as described [24]. The treadmill belt speed was set at 
10 m/min for the initial 5 minutes, and increased by 5 m/min every 5 minutes. The test 
was terminated within 30 minutes or when the rat exhibited signs of exhaustion. 
 
Langendorff RV-IR model 
The Langendorff preparation used an isolated perfused heart system (Radnoti; Monrovia, 
CA, USA). The model was performed as described previously for the LV [10,25], except 
the ventricular balloon was placed in the RV. Rats were anesthetized with Ketamine 75 
mg/kg plus Xylazine 10 mg/kg (IP). Blood was heparinized and their hearts were rapidly 
removed. The aorta was mounted on a Langendorff apparatus and perfused with 
oxygenated KH buffer (95% O2 + 5% CO2) at 37°C at a constant pressure of 85 cmH2O. 
RV pressure was measured by a fluid-filled balloon in the RV, which was connected to a 
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pressure transducer (Harvard Apparatus; Holliston, MA, USA). High fidelity signals 
were recorded using PowerLab 8/35 data acquisition hardware and analyzed using 
LabChart Pro 8 software (AD Instruments; Colorado Springs, CO, USA).  
 
IR protocol: Hearts were stabilized for 10-20 min before beginning the experimental 
protocol. Mdivi-1 (25 μM) or P110 (1 μM) was added to the perfusate 10 min prior to 
ischemia. DMSO and TAT were used as vehicle control for Mdivi-1 and P110, 
respectively. Two consecutive cycles of 15 min of global ischemia followed by 15 min of 
reperfusion were performed in the RV Langendorff preparation. In hearts used solely as a 
source of tissue for immunoblotting, aconitase activity assay or transmission electron 
microscopy (TEM), either a single cycle of IR or 45 min of perfusion without IR was 
performed. 
 
Immunoblotting 
At the end of the Langendorff RV-IR experiment, the RV was dissected free from the LV 
plus septum (LV+S) and weighed. The tissues were then preserved at -80 °C for 
subsequent immunoblotting. RV proteins were extracted from the various subcellular 
compartments using a cytoplasmic, mitochondrial and nuclear protein extraction kit (Cat 
#: MCN-002, ZmTech Scientifique; Montreal, QC, Canada). The following antibodies 
were used: anti-Drp1 antibody (1:500; Cat #: ab56788, Abcam; Cambridge, MA, USA), 
anti-β-tubulin antibody (1:1000; Cat #: 32-2600, Invitrogen; Grand Island, NY, USA), 
anti-voltage-dependent anion channel (VDAC) antibody (1:1000; Cat #: 4866, Cell 
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Signaling; Whitby, ON, Canada), anti-phospho-Drp1 (serine 616) antibody (1:1000; Cat 
#: 3455S, Cell signaling; Whitby, ON, Canada), and anti-Fis1 antibody (1:500; Cat #: 
10956-1-AP, ProteinTech; Rosemont, IL, USA). β-tubulin and VDAC were used as 
cytoplasmic and mitochondrial loading controls, respectively. 
 
Transmission electron microscopy (TEM)  
After the Langendorff experiment, the RV was immediately fixed in 4% formaldehyde 
and 1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) overnight or longer. The 
tissue was then immersed in 2% sodium cocodylate buffer solution and post-fixed in 1% 
osmium tetroxide in 0.1 M phosphate buffer for 1 hour. After standard dehydration, 
embedding and sectioning, the grids with tissue sections were stained with 5% uranyl 
acetate for 15 min followed by staining with 3% lead citrate for 5 min. Images were 
collected using a transmission electron microscope (Tecnai Osiris; FEI, Hillsboro, OR, 
USA) at 80 kV with a Gatan charge-coupled device camera. Mitochondria were traced 
manually for area measurement using Leica imaging software (Version 4.7, Leica 
Microsystems; Wetzlar, Germany). Mitochondrial ultrastructure was graded and assigned 
a numerical score as described previously [26]. A score of 0 indicates a normal 
mitochondrion, whilst numbers 1 through 3 indicate progressive swelling of mitochondria 
and disintegration of cristae, with higher numbers reflecting more severe swelling and 
disintegration. A minimum of 120 mitochondria/group was analyzed. 
Confocal microscopy on mitochondrial membrane potential of RV tissue 
Mitochondrial membrane potential was measured in RV myocytes using 
tetramethylrhodamine methyl ester (TMRM; Cat #: T668, Lifetechnologies; Carlsbad, 
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CA, USA), a potentiometric dye which is more fluorescent when membrane potential is 
more negative. Membrane potential was measured in RVs post Langendorff experiments 
and in RVs freshly harvested from rats that did not undergo a Langendorff experiment. In 
both cases the RV was immediately incubated in KH buffer containing NucBlue® Live 
ReadyProbes® Reagent (2 drops/mL) following the manufacturer's protocol (Cat #: 
R37605, Life Technologies; Carlsbad, CA, USA) and TMRM (250 nM) at 37 °C for 
30~45 min. The tissue was then imaged using a Leica SP8 confocal, laser-scanning 
microscope (Leica Microsystems; Wetzlar, Germany) with a 1.40NA, 63X oil immersion 
objective. A frame was taken in every ~16 seconds over a 5~10 min period. TMRM 
intensity was measured using ImageJ software (National Institutes of Health; Bethesda, 
MD, USA). 
 
Confocal microscopy of RV vasculature 
After rats were anesthetized with Ketamine 75mg/kg plus Xylazine 10mg/kg (IP), the 
right internal jugular vein was cannulated for infusion of 1 mL PBS containing 10 mg of 
albumin–FITC (Cat #: A9771, Sigma, St. Louis, MO, USA). 30 seconds after the 
infusion, the chest was opened and the main pulmonary artery, ascending aorta, superior 
and inferior vena cava, and mitral valve were occluded with suture to prevent the leaking 
of the blood out of the heart vasculature. The whole heart was then isolated and dissected 
for imaging of the RV free wall using a Leica SP8 confocal laser scanning microscope 
(Leica Microsystems; Wetzlar, Germany) with a 1.40NA, 40X oil immersion objective. 
Z-stacking to a depth of 12 μm over an area of ~ 1 mm × ~ 1 mm from 1~3 spots per each 
RV was performed. The Z-stacked images were then projected to view the vessels that 
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contain albumin–FITC. The intensity of fluorescent signal for albumin–FITC was 
quantified using ImageJ software (National Institutes of Health; Bethesda, MD, USA) to 
quantify patent, perfused vessel. For each spot, 5~11 regions of interest with a size of 200 
μm × 200 μm were analyzed and averaged to obtain a mean intensity. 
 
Aconitase activity assay 
The aconitase activity assay was performed according to the manufacturer’s protocol. 
Briefly, isolated mitochondrial pellets obtained from the RVs after the Langendorff 
experiment were disrupted via sonication and extracted using Aconitase Activity Assay 
kit components (Cat #: ab110169, Abcam; Cambridge, MA, USA). Enzyme activity was 
measured by quantifying the conversion of citrate to isocitrate. Isocitrate was further 
processed and resulted in a product that converts a colorless probe to a colored product in 
proportion to aconitase activity. 
 
Statistical analysis 
All of the data are reported as mean ± standard error of the mean (SEM). A two-tailed, 
Student’s t-test was used for comparison between 2 groups. One-way analysis of variance 
(ANOVA) was used for comparison between > 2 groups, followed by Tukey multiple-
comparison post hoc test.  A P < 0.05 was considered statistically significant.  
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RESULTS 
PAH and RVH in MCT rats were confirmed by echocardiography  
At week 4 post-injection of MCT or PBS, body weight was significantly less in MCT vs. 
control rats (330±11 vs. 516±9 g, P < 0.001). Compared to control, MCT rats had shorter 
PAAT (19±0.5 vs. 33±1 ms, P < 0.001; Fig. 1A) and reduced CO (73±4 vs. 136±6 
ml/min, P < 0.001; Fig. 1B), findings which are consistent with PAH. Likewise, MCT 
caused RV hypertrophy (RVH), as indicated by increased RVFW diastolic thickness 
(1.42±0.05 vs. 0.63±0.02 mm, P < 0.001; Fig. 1C) and Fulton index (RV/LV+S) 
(0.58±0.04 vs. 0.26±0.04, P < 0.001; Fig.1D) in MCT vs. control rats. RVFW systolic 
thickening and TAPSE were reduced in MCT rats compared to control (31±3 vs. 100±5, 
P < 0.001; Fig. 1E, and 1.6±0.1 vs. 2.9±0.1 mm, P < 0.001; Fig. 1F, respectively), 
consistent with RV dysfunction. Treadmill distance was also reduced in MCT vs. control 
rats (32±8 vs. 193±18 m, P < 0.001; Fig. 1G). 
 
MCT-PAH RV displays microvascular rarefaction  
The number of small blood vessels (5~15 μm in diameter) was significantly less in MCT 
versus control RV, as indicated by the fluorescent intensity over a line of 500 μm (Fig. 
2A). Confirmation of this finding was evidenced by the significantly reduced area 
intensity of the blood vessels’ fluorescent signal in MCT RVs compared to the control 
(Fig. 2B).  
 
Mdivi-1 and P110 attenuate IR-induced RV diastolic dysfunction  
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RVs from MCT rats developed greater RV systolic pressure (RVSP) than the control 
RVs, but had similar RVEDP at baseline (Fig. 3). Following IR, both RVSP and RVEDP 
increased in both control and MCT RVs (Fig. 3A&C). Neither of the vehicle controls 
(DMSO or TAT) had any hemodynamic effect (Supplemental Fig. S1), so these two 
groups were combined and reported as a vehicle control group in all the experimental 
studies. Both Mdivi-1 and P110 significantly reduced RVEDP post-IR compared to 
vehicle control in control and MCT RVs (Fig. 3B&D). Interestingly, while P110 had no 
effect on RVSP, Mdivi-1 tended to reduce post reperfusion RVSP in control RVs, though 
not significantly (Fig. 3B).  
 
Mdivi-1 and P110 protect mitochondrial network structure and membrane potential 
from IR  
Control RVs that did not undergo IR had mitochondria that were organized in regular 
grids and were strongly polarized, evident from high uptake of TMRM (Fig. 4A; 
Supplemental video S1). In contrast in MCT RVs that did not undergo IR, mitochondria 
were fragmented and TMRM intensity was significantly reduced (Fig. 4; Supplemental 
video S5). IR caused a disruption in the mitochondrial network of control RVs, but did 
not exacerbate the already fragmented mitochondrial network of MCT RVs. Both Mdivi-
1 and P110 improved the mitochondria network in control and MCT RVs with IR (Fig. 4). 
Following IR, TMRM intensity decreased in control RVs (P < 0.05), but did not further 
decreased in the already depolarized mitochondria of MCT RVs. Both Mdivi-1 and P110 
increased TMRM intensity in both control and MCT RVs compared to the vehicle control 
(P < 0.05; Fig. 4B; Supplemental videos). 
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Mdivi-1 and P110 preserve mitochondrial morphology and ultrastructure  
Without IR, mitochondria in MCT RVs already displayed swelling with less dense cristae 
on TEM compared to control RVs, as indicated by greater mitochondrial area and a lower 
percentage of morphologically normal mitochondria (Fig. 5; Supplemental Fig. S2). 
Following IR, mitochondria in both control and MCT RVs were swollen with less dense 
cristae. Both Mdivi-1 and P110 preserved mitochondrial morphology and ultrastructure, 
reducing mitochondrial area and increasing the % of mitochondria that were scored as 
normal, in both control and MCT RVs (Fig. 5; Supplemental Fig. S2). 
 
Aconitase activity was reduced by IR in control RV to levels seen in PAH RV 
Without IR, aconitase activity was depressed in MCT RVs compared to control RVs (P < 
0.05; Fig. 6). Following IR, aconitase activity was significantly decreased in control RVs 
to levels seen at baseline in MCT RVs (Fig. 6). The treatment of Mdivi-1 or P110 did not 
restore the aconitase activity for either control or MCT RVs with IR (Supplemental Fig. 
S3). 
 
Mdivi-1 and P110 decreased mitochondrial Drp1 expression  
There was increased Drp1 in the mitochondrial fraction of MCT RVs at baseline (Fig. 7), 
whereas cytoplasmic Drp1 levels tended to be lower in MCT vs. control RVs 
(Supplemental Figs. 4A). In both control and MCT RVs, IR increased mitochondrial 
translocation of Drp1 (P<0.05; Fig. 7). Drp1 phosphorylation at serine 616 in 
mitochondria increased significantly in control RVs with IR (P < 0.05; Supplemental Fig. 
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S4B) but not in MCT RVs with IR (data not shown). Treatment with either Mdivi-1 or 
P110 reduced mitochondrial translocation of Drp1, though this was statistically 
significant only in MCT RVs (Fig. 7). Finally, mitochondrial Fis1 expression was not 
significantly different between control and MCT RVs, even with IR (Supplemental Fig. 
S4C). 
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DISCUSSION 
This study describes a role for ischemia-mediated mitochondrial fission in causing 
diastolic dysfunction of the RV and impaired functional capacity in PAH. RV ischemia in 
PAH may occur for several reasons. In vivo, it may result from capillary rarefaction or 
impaired coronary perfusion pressure in the right coronary artery. In this study, we 
assessed the consequences of a chronic ischemic RV burden in PAH (by examining the 
RV microvasculature and RV function in MCT-PAH in vivo) and the resilience of the 
RV to more extreme ischemia (assessed using global ischemic challenges in the ex vivo 
RV Langendorff model). In both instances, ischemia leads to mitochondrial fission and 
depolarization in RV myocytes and this change in mitochondrial dynamics ultimately 
causes RV diastolic dysfunction (ex vivo) (Fig. 3) and functional impairment (in vivo) 
(Fig. 1).  
 
This study revealed four significant findings. First, when exposed to IR, the RV, whether 
from normal rats or MCT-PAH rats, develops diastolic dysfunction, manifesting as an 
elevation of RVEDP. Second, this RV-IR response is due to the activation and 
translocation of the fission mediator Drp1 to the mitochondria where it causes 
mitochondrial fission, depolarization, swelling, and oxidative damage. Third, in the RV 
of MCT-PAH rats, the baseline mitochondrial phenotype (increased mitochondrial Drp1 
expression, disruption of cristae, and depolarization) resembles that induced by global IR 
in the normal RV. This is consistent with the interpretation that ischemic mitochondrial 
fission in vivo creates a basal mitochondriopathy that contributes to RV dysfunction in 
the MCT-PAH model. Fourth, we demonstrate that two chemically and mechanistically 
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distinct Drp1 inhibitors (Mdivi-1 and P110) preserve diastolic function post RV-IR via 
inhibiting Drp1-induced fission. In aggregate, these discoveries highlight the importance 
of the Drp1-Fis1 axis in mediating RV dysfunction in PAH. 
 
Compared to control, MCT rats had significantly elevated pulmonary arterial pressures, 
as indicated by reduced PAAT (Fig. 1A). As expected, there was substantial RVH (both 
RVFW diastolic thickness and RV mass were increased, Fig. 1C&D). MCT RVs 
displayed microvasculature rarefaction (Fig. 2), consistent with previous studies [3,4]. 
Our group has previously shown that compared to the control, MCT RVs exhibited 
reduced coronary flow measured in the RV Langendorff experiment, reduced expression 
of vascular endothelial growth factor, and increased lactate production [4]. In aggregate 
these data indicate that the MCT RV is indeed ischemic. Although these are not novel 
findings, we document that they resulted in RV dysfunction, evident from the 
significantly reduced CO (Fig. 1B), decreased RVFW thickening, and decreased TAPSE 
(Fig. 1E&F). The impairment of RV function was associated with reduced functional 
capacity, apparent as shorter treadmill distances in MCT vs. control rats (Fig. 1G). In the 
ex vivo Langendorff RV-IR model, MCT rats developed greater RV systolic pressures 
than the control. This increased capacity for pressure development in a load-independent 
model relates primarily to the increase in RV mass in MCT-PAH.  In aggregate, these 
data show a phenotype of RV failure in the MCT model similar to that seen in PAH 
patients. 
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Our findings in RV-IR are consistent with but extend prior work on the role of Drp1-
mediated fission in LV-IR. Sharp et al. [10] previously reported the IR-induced rise in 
LVEDP in normal rats, assessed using an ex vivo LV Langendorff model. Our 
observations of the RV-IR-induced increase in EDP are consistent with those of the LV-
IR [10]. However, both normal and hypertrophied RVs retained systolic contractility 
despite two cycles of IR (Fig. 3), which contrasts to the LV following IR, which 
demonstrates decreased contractile capacity [10]. Inhibiting mitochondrial fission using 
Mdivi-1 or P110 ex vivo or in vivo protects the LV from many insults, including global 
IR in the Langendorff model [10,13], coronary artery occlusion [12,13], aortic banding 
[21], and KCl-induced cardiac arrest [11]. We have extended these studies, demonstrating 
the benefits of Mdivi-1 and P110 in RV-IR, (Fig. 3). We have also demonstrated the 
mechanism by which ischemia occurs and show that it is the interaction of Drp1 and Fis1, 
which is critical in causing RV dysfunction. 
 
IR activates Drp1 in many tissues, including rodent LV cardiac myocytes, renal proximal 
tubular cells, and retinal ganglion cells [10,11,13,27,28]. Drp1 is also activated in 
pulmonary artery smooth muscle cells in human and experimental PAH [20]. In the heart 
Drp1 activation appears relevant as a mechanism of myocyte injury, likely because 
fission increases ROS production [10]. In contrast, Drp1 activation in the pulmonary 
vasculature in PAH is reflective of pathologic rates of mitotic fission, which supports 
accelerated mitosis (reviewed in [17]). One might expect that inhibiting Drp1 in PAH 
would benefit the RV (providing protection from ischemia) and the pulmonary 
vasculature (serving as an antiproliferative agent).  
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Drp1 activation can result either from an increase in phosphorylation at serine 616 or a 
decrease in phosphorylation at serine 637. After LV-IR or cardiac arrest, a decrease in 
Drp1 phosphorylation at serine 637 appears pathologically important [10,11,27]. Serine 
637 dephosphorylation results from calcium-induced activation of the phosphatase, 
calcineurin [10]. However, increased Drp1 phosphorylation at serine 616 in pulmonary 
artery smooth muscle cells appears to be the predominant mechanism of Drp1 activation 
in the vasculature [20]. This phosphoform seems particularly important in enhancing 
mitotic fission and participates in the hyperproliferative phenotype of these cells. As 
expected with ischemia-induced Drp1 translocation to the mitochondria, the cytoplasmic 
(inactive) form of the enzyme was reduced in MCT-PAH RV (Fig. 7; Supplemental Fig. 
S4). Likewise, in the normal RV, IR increased the accumulation of activated Drp1, 
including the activated serine 616 isoform, at the OMM while depleting the cytoplasmic 
Drp1 pool (Fig. 7; Supplemental Fig. S4).  However, we did not compare the roles of 
these two phosphoforms of Drp1 (i.e., serine 616 and 637) in RV-IR.  
 
IR not only causes mitochondrial fission; several other changes occur, notably 
mitochondrial depolarization and swelling. Ikeda et al. found that adenovirus-mediated 
Drp1 overexpression is sufficient to depolarize mitochondrial membrane potential in 
mouse cardiomyocytes [29]. Consistent with this, we demonstrate that MCT RV 
myocytes not only have an increased mitochondrial Drp1 pool, but also have markedly 
depolarized mitochondria, as measured with live cell imaging (Fig. 4). Indeed, the degree 
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of mitochondrial depolarization at baseline in MCT-PAH RV is qualitatively similar to 
that observed in normal RV following IR (Fig. 4). These findings in the RV are 
consistent with studies of LV-derived adult murine and neonatal rat cardiomyocytes, in 
which IR depolarizes mitochondrial membrane potential [12,30]. Mitochondrial 
depolarization is a prelude to myocyte death, and inhibiting Drp1 can prevent 
depolarization stimulated by apoptosis-inducers such as cisplatin, staurosporine and 
etoposide [31].  
 
IR also alters mitochondrial morphology and ultrastructure, causing mitochondrial 
swelling, loss of matrix density and cristae disintegration [26,32]. We observed these 
mitochondrial changes in RV myocyte mitochondria, both at baseline, in the MCT-PAH 
model, and with IR in the normal RVs (Fig. 5). In contrast, mitochondrial size (cross-
sectional area) decreased with IR in rat LV ex vivo [13] and with cardiac arrest in mouse 
LV in vivo [11]. Such morphologic discrepancies may reflect chamber-specific 
differences in mitochondrial sensitivity to IR or could possibly due to the difference in 
the experimental protocol since both these LV protocols had much longer periods of 
reperfusion prior to imaging mitochondrial morphology.  
 
Finally, in the LV, ischemia causes mitochondrial oxidant damage with increased 
production of ROS, as indicated by reduced LV aconitase activity [11,30]. Consistent 
with these studies, we demonstrate the loss of aconitase activity in normal RV with IR. 
As with many of the measures of mitochondrial health, MCT-RV derived mitochondria 
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had basal depression of aconitase activity similar in severity to that induced in normal 
RVs following global IR (Fig. 6).  
 
We want to emphasize from these data that MCT RV at baseline (without IR) shares 
many of the abnormalities of that occur in normal RV with IR, including Drp1 
translocation to mitochondria, mitochondrial fission, mitochondrial depolarization, 
mitochondrial swelling, and a decrease in aconitase activity. This is consistent with the 
studies on mitochondrial fission in RV fibroblast from MCT rats [33] and pulmonary 
artery smooth muscle cells and fibroblasts from human PAH patients [20,34,35] and on 
mitochondrial Drp1 translocation in pulmonary artery smooth muscle cells with PAH 
[20]. The MCT RV, without an ex vivo IR challenge, is already ischemic due to RV 
microvasculature rarefaction (Fig. 2). Moreover, mitochondria from MCT RV are already 
at a maximally impaired level such that experimental RV-IR does not cause further 
mitochondrial damage (Fig. 4, 5&6); however, mitochondrial Drp1 levels are further 
increased (Fig. 7). 
 
We demonstrate the therapeutic benefit of inhibiting Drp1, using Mdivi-1, or inhibiting 
the Drp1-Fis1 interaction, using P110. These therapies not only reduce RVEDP but also 
restore the mitochondrial structure and function, counteracting IR damage. Several 
studies have found that Mdivi-1 and P110 can restore mitochondrial Drp1 level and 
preserve mitochondrial structure and function [10,11,13]. We extended these studies, 
demonstrating that both Mdivi-1 and P110 effectively restore mitochondrial membrane 
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potential and mitochondrial cristae integration and prevent mitochondrial swelling (Fig. 
4&5) by preventing the translocation of Drp1 to mitochondria (Fig. 7), resulting in the 
improvement of RV diastolic function ex vivo in both normal and PAH rats (Fig. 3). 
 
In addition, while Mdivi-1 inhibits Drp1 GTPase activity, and does not help us 
distinguish which binding partners are relevant to ischemic injury, P110 only blocks the 
interaction between Drp1 and Fis1. The observation that P110 is as effective as Mdivi-1 
in restoring mitochondrial Drp1 level (Fig. 7), preserving mitochondrial structure and 
function (Fig. 4&5) and improving RV diastolic function with IR (Fig. 3), identifies Fis1 
as the relevant Drp1 binding partner in RV-IR and excludes a crucial role for MFF, 
MiD49, and MiD51. This is consistent with an immunoprecipitation study of LV 
myocyte exposed to IR, which found that Drp1 binds to Fis1, but not MFF or MiD51 
[13].  
 
Taking all of these findings together, a proposed mechanistic pathway for Drp1 activation 
along with the intervention of Mdivi-1 and P110 is presented in Fig. 8. The RV is 
ischemic in PAH [1,2] and Drp1 plays a role in the ischemia-induced RV diastolic 
dysfunction (Fig. 8). Therefore, Drp1 is a promising therapeutic target. Inhibition of Drp1 
GTPase activity, via drugs such as Mdivi-1, or Drp1-Fis1 interaction, via disruptive 
peptides such as P110, can improve mitochondrial structure and function and thus 
improve RV function in IR injury. Targeting Drp1 or Drp1-Fis1 interaction to prevent 
fission may be a novel cardioprotective strategy in PAH. 
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Limitations 
Several limitations are acknowledged. First, the effects of Mdivi-1 or P110 were not 
studied in vivo in MCT PAH. However, we have previously demonstrated benefits from 
Mdivi-1 on the pulmonary vasculature in both MCT [20] and chronic hypoxia-SU5416 
rat models [34] of PAH. In addition, several studies have shown the benefits of Mdivi-1 
and P110 in the LV subjected to IR injury or cardiac arrest [11-13]. Thus further study is 
required to evaluate whether Mdivi-1 and P110 improve RV function in vivo in PAH. 
Second, we observed an ischemia-induced increase in Drp1 phosphorylation at serine 616 
only in the normal RV but not in the MCT-PAH RV with IR. The basis for this is 
uncertain and further studies to measure phosphorylation of serine 637 and 616 may be 
useful. Third, although aconitase activity is an indicator of ROS production, direct 
measurement of ROS production was not performed. Fourth, we did not perform 
immunoprecipitation studies on RV myocytes to corroborate the findings of our P110 
experiments. These additional experiments might help confirm the importance of Fis1 as 
the unique Drp1 binding partner in RV ischemia, although the specificity of P110 is 
compelling. Fifth, no single model replicates all features of the human PAH [36], and 
even in human PAH there is phenotypic and histological variability amongst individual 
patients [37]. We chose MCT rat model of PAH because this model captures the aspect of 
the phenotype of human PAH which was the main focus of our research, namely the 
development of RV failure due to maladaptive RVH and ischemia [37]. We speculate that 
chronic hypoxia-SU5416 rats (especially the Fischer rats) [36] would also develop 
ischemic RV failure. Sixth, we have previously shown that compared to the control, MCT 
RVs displayed decreased oxygen consumption, increased glycolysis, and increased 2-
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fluoro-2-deoxy-D-glucose uptake. This reflects upregulation of uncoupled glycolysis, due 
in part to inhibitory phosphorylation of pyruvate dehydrogenase (PDH) [23]. We have 
also shown that dichloroacetate (DCA) increased glucose oxidation and improved cardiac 
function in MCT rats, consistent to the study by Ussher et al. who demonstrated 
protection against IR resulted from DCA-mediated activation of PDH [38]. While the 
metabolic function in RV is important to cardiac function, the focus of the current study 
is the upstream mediator, namely Drp1, which regulates mitochondrial fission and 
triggers RV dysfunction in the MCT RV. Fission-mediated dysfunction of the RV is 
likely reinforced by metabolic dysregulation. Finally, we acknowledge that our finding of 
mitochondrial depolarization in MCT RV differs from studies by Nagendran et al. [39] 
and Sutendra et al. [40], who, using similar optical techniques and TMRM, found that RV 
myocyte mitochondrial membrane potential was hyperpolarized in MCT RV. The reason 
for this discrepancy is unknown. 
 
Conclusions 
We conclude that in MCT-induced PAH and ex vivo IR, Drp1 activation impairs RV 
lusitropy. Ischemia-induced RV mitochondrial fission primarily results from fission 
caused by interaction between activated Drp1 and Fis1. Inhibition of Drp1 GTPase 
activity or Drp1-Fis1 interaction can improve RV diastolic function. Drp1 inhibition is a 
promising therapeutic strategy to improve RV diastolic function in PAH or other 
conditions in which the RV is exposed to IR, such as pulmonary embolism or 
cardiopulmonary bypass. 
27 
Acknowledgement 
This study was supported in part by U.S. National Institutes of Health (NIH) grants NIH 
R01HL113003 (S.L.A.), NIH R01HL071115 (S.L.A.), and NIH 1R01HL133675-01 
(W.W.S), Canada Foundation for Innovation 229252 and 33012 (S.L.A.), Tier 1 Canada 
Research Chair in Mitochondrial Dynamics and Translational Medicine 950-229252 
(S.L.A.), the William J. Henderson Foundation (S.L.A.), and Canadian Vascular Network 
Scholar Award (L.T.; A.D.; K.D.S.; D.W.). 
 
Conflict of interest 
The authors declare that they have no conflict of interest. 
 
28 
References 
1. Vogel-Claussen J, Skrok J, Shehata ML, Singh S, Sibley CT, Boyce DM, Lechtzin N, 
Girgis RE, Mathai SC, Goldstein TA, Zheng J, Lima JA, Bluemke DA, Hassoun PM 
(2011) Right and left ventricular myocardial perfusion reserves correlate with right 
ventricular function and pulmonary hemodynamics in patients with pulmonary arterial 
hypertension. Radiology 258 (1):119-127. doi:10.1148/radiol.10100725 
2. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P, 
Burakowski J, Wawrzynska L (2003) Detectable serum cardiac troponin T as a marker of 
poor prognosis among patients with chronic precapillary pulmonary hypertension. 
Circulation 108 (7):844-848. doi:10.1161/01.CIR.0000084544.54513.E2 
3. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, 
Ockaili R, McCord JM, Voelkel NF (2009) Chronic pulmonary artery pressure elevation 
is insufficient to explain right heart failure. Circulation 120 (20):1951-1960. 
doi:10.1161/CIRCULATIONAHA.109.883843 
4. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL (2013) Cardiac 
glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in 
pulmonary hypertension. Journal of molecular medicine 91 (10):1185-1197. 
doi:10.1007/s00109-013-1064-7 
5. Bian X, Williams AG, Jr., Gwirtz PA, Downey HF (1998) Right coronary 
autoregulation in conscious, chronically instrumented dogs. The American journal of 
physiology 275 (1 Pt 2):H169-175 
6. Vlahakes GJ, Baer RW, Uhlig PN, Verrier ED, Bristow JD, Hoffmann JI (1982) 
Adrenergic influence in the coronary circulation of conscious dogs during maximal 
vasodilation with adenosine. Circulation research 51 (3):371-384 
7. Minai OA, Yared JP, Kaw R, Subramaniam K, Hill NS (2013) Perioperative risk and 
management in patients with pulmonary hypertension. Chest 144 (1):329-340. 
doi:10.1378/chest.12-1752 
8. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Bottiger BW, Callaway C, Clark 
RS, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Jr., Merchant RM, 
Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, 
Sellke FW, Spaulding C, Sunde K, Vanden Hoek T (2008) Post-cardiac arrest syndrome: 
epidemiology, pathophysiology, treatment, and prognostication. A consensus statement 
from the International Liaison Committee on Resuscitation (American Heart Association, 
Australian and New Zealand Council on Resuscitation, European Resuscitation Council, 
Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation 
Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart 
Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular 
Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical 
Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation 118 
(23):2452-2483. doi:10.1161/CIRCULATIONAHA.108.190652 
9. Zia A, Kern KB (2011) Management of postcardiac arrest myocardial dysfunction. 
Current opinion in critical care 17 (3):241-246. doi:10.1097/MCC.0b013e3283447759 
10. Sharp WW, Fang YH, Han M, Zhang HJ, Hong Z, Banathy A, Morrow E, Ryan JJ, 
Archer SL (2014) Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in 
myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce 
29 
mitochondrial fission. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 28 (1):316-326. doi:10.1096/fj.12-226225 
11. Sharp WW, Beiser DG, Fang YH, Han M, Piao L, Varughese J, Archer SL (2015) 
Inhibition of the mitochondrial fission protein dynamin-related protein 1 improves 
survival in a murine cardiac arrest model. Critical care medicine 43 (2):e38-47. 
doi:10.1097/CCM.0000000000000817 
12. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ (2010) 
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. 
Circulation 121 (18):2012-2022. doi:10.1161/CIRCULATIONAHA.109.906610 
13. Disatnik MH, Ferreira JC, Campos JC, Gomes KS, Dourado PM, Qi X, Mochly-
Rosen D (2013) Acute inhibition of excessive mitochondrial fission after myocardial 
infarction prevents long-term cardiac dysfunction. Journal of the American Heart 
Association 2 (5):e000461. doi:10.1161/JAHA.113.000461 
14. Loson OC, Song Z, Chen H, Chan DC (2013) Fis1, Mff, MiD49, and MiD51 mediate 
Drp1 recruitment in mitochondrial fission. Molecular biology of the cell 24 (5):659-667. 
doi:10.1091/mbc.E12-10-0721 
15. Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, Mihara K (2010) 
Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial 
fission in mammalian cells. The Journal of cell biology 191 (6):1141-1158. 
doi:10.1083/jcb.201007152 
16. Zhao J, Liu T, Jin S, Wang X, Qu M, Uhlen P, Tomilin N, Shupliakov O, Lendahl U, 
Nister M (2011) Human MIEF1 recruits Drp1 to mitochondrial outer membranes and 
promotes mitochondrial fusion rather than fission. The EMBO journal 30 (14):2762-
2778. doi:10.1038/emboj.2011.198 
17. Archer SL (2013) Mitochondrial dynamics--mitochondrial fission and fusion in 
human diseases. The New England journal of medicine 369 (23):2236-2251. 
doi:10.1056/NEJMra1215233 
18. Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, 
Bernardi P, Scorrano L (2008) Dephosphorylation by calcineurin regulates translocation 
of Drp1 to mitochondria. Proceedings of the National Academy of Sciences of the United 
States of America 105 (41):15803-15808. doi:10.1073/pnas.0808249105 
19. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K (2007) Mitotic phosphorylation of 
dynamin-related GTPase Drp1 participates in mitochondrial fission. The Journal of 
biological chemistry 282 (15):11521-11529. doi:10.1074/jbc.M607279200 
20. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, 
Zhang HJ, Pogoriler J, Chen Y, Morrow E, Weir EK, Rehman J, Archer SL (2012) 
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits 
hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in 
pulmonary hypertension. Circulation research 110 (11):1484-1497. 
doi:10.1161/CIRCRESAHA.111.263848 
21. Givvimani S, Munjal C, Tyagi N, Sen U, Metreveli N, Tyagi SC (2012) 
Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload 
induced heart failure. PloS one 7 (3):e32388. doi:10.1371/journal.pone.0032388 
22. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL (2010) Validation of high-
resolution echocardiography and magnetic resonance imaging vs. high-fidelity 
catheterization in experimental pulmonary hypertension. American journal of physiology 
30 
Lung cellular and molecular physiology 299 (3):L401-412. 
doi:10.1152/ajplung.00114.2010 
23. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, 
Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL (2010) The inhibition of 
pyruvate dehydrogenase kinase improves impaired cardiac function and electrical 
remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating 
right ventricle. Journal of molecular medicine 88 (1):47-60. doi:10.1007/s00109-009-
0524-6 
24. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer 
SL (2012) Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: 
exploiting Randle's cycle. Journal of molecular medicine 90 (1):31-43. 
doi:10.1007/s00109-011-0804-9 
25. Henry TD, Archer SL, Nelson D, Weir EK, From AH (1990) Enhanced 
chemiluminescence as a measure of oxygen-derived free radical generation during 
ischemia and reperfusion. Circulation research 67 (6):1453-1461 
26. Edoute Y, van der Merwe E, Sanan D, Kotze JC, Steinmann C, Lochner A (1983) 
Normothermic ischemic cardiac arrest of the isolated working rat heart. Effects of time 
and reperfusion on myocardial ultrastructure, mitochondrial oxidative function, and 
mechanical recovery. Circulation research 53 (5):663-678 
27. Cho SG, Du Q, Huang S, Dong Z (2010) Drp1 dephosphorylation in ATP depletion-
induced mitochondrial injury and tubular cell apoptosis. American journal of physiology 
Renal physiology 299 (1):F199-206. doi:10.1152/ajprenal.00716.2009 
28. Park SW, Kim KY, Lindsey JD, Dai Y, Heo H, Nguyen DH, Ellisman MH, Weinreb 
RN, Ju WK (2011) A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell 
survival in acute ischemic mouse retina. Investigative ophthalmology & visual science 52 
(5):2837-2843. doi:10.1167/iovs.09-5010 
29. Ikeda Y, Shirakabe A, Maejima Y, Zhai P, Sciarretta S, Toli J, Nomura M, Mihara K, 
Egashira K, Ohishi M, Abdellatif M, Sadoshima J (2015) Endogenous Drp1 mediates 
mitochondrial autophagy and protects the heart against energy stress. Circulation research 
116 (2):264-278. doi:10.1161/CIRCRESAHA.116.303356 
30. Dezfulian C, Shiva S, Alekseyenko A, Pendyal A, Beiser DG, Munasinghe JP, 
Anderson SA, Chesley CF, Vanden Hoek TL, Gladwin MT (2009) Nitrite therapy after 
cardiac arrest reduces reactive oxygen species generation, improves cardiac and 
neurological function, and enhances survival via reversible inhibition of mitochondrial 
complex I. Circulation 120 (10):897-905. doi:10.1161/CIRCULATIONAHA.109.853267 
31. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith 
CL, Youle RJ (2001) The role of dynamin-related protein 1, a mediator of mitochondrial 
fission, in apoptosis. Developmental cell 1 (4):515-525 
32. Yeh ST, Lee HL, Aune SE, Chen CL, Chen YR, Angelos MG (2009) Preservation of 
mitochondrial function with cardiopulmonary resuscitation in prolonged cardiac arrest in 
rats. Journal of molecular and cellular cardiology 47 (6):789-797. 
doi:10.1016/j.yjmcc.2009.09.003 
33. Tian L, Hong Z, Feng MG, Chen KH, Dasgupta AA, S.L. (2015) Role of 
mitochondrial-metabolic changes in the right ventricular fibroblasts in experimental 
pulmonary arterial hypertension. Paper presented at the The PVRI Annual World 
Congress, Guangzhou, China,  
31 
34. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Hong Z, 
Ericson K, Zhang HJ, Han M, Haney CR, Chen CT, Sharp WW, Archer SL (2013) 
PGC1alpha-mediated mitofusin-2 deficiency in female rats and humans with pulmonary 
arterial hypertension. American journal of respiratory and critical care medicine 187 
(8):865-878. doi:10.1164/rccm.201209-1687OC 
35. Plecita-Hlavata L, Tauber J, Li M, Zhang H, Flockton AR, Pullamsetti SS, 
Chelladurai P, D'Alessandro A, El Kasmi KC, Jezek P, Stenmark KR (2016) Constitutive 
Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. 
American journal of respiratory cell and molecular biology 55 (1):47-57. 
doi:10.1165/rcmb.2015-0142OC 
36. Jiang B, Deng Y, Suen C, Taha M, Chaudhary KR, Courtman DW, Stewart DJ (2016) 
Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary 
Arterial Hypertension. American journal of respiratory cell and molecular biology 54 
(4):461-468. doi:10.1165/rcmb.2014-0488OC 
37. Ryan JJ, Marsboom G, Archer SL (2013) Rodent models of group 1 pulmonary 
hypertension. Handbook of experimental pharmacology 218:105-149. doi:10.1007/978-3-
642-38664-0_5 
38. Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, Wagg CS, 
Jaswal JS, Harris RA, Clanachan AS, Dyck JR, Lopaschuk GD (2012) Stimulation of 
glucose oxidation protects against acute myocardial infarction and reperfusion injury. 
Cardiovascular research 94 (2):359-369. doi:10.1093/cvr/cvs129 
39. Nagendran J, Gurtu V, Fu DZ, Dyck JR, Haromy A, Ross DB, Rebeyka IM, 
Michelakis ED (2008) A dynamic and chamber-specific mitochondrial remodeling in 
right ventricular hypertrophy can be therapeutically targeted. The Journal of thoracic and 
cardiovascular surgery 136 (1):168-178, 178 e161-163. doi:10.1016/j.jtcvs.2008.01.040 
40. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, 
Michelakis ED (2013) A metabolic remodeling in right ventricular hypertrophy is 
associated with decreased angiogenesis and a transition from a compensated to a 
decompensated state in pulmonary hypertension. Journal of molecular medicine 91 
(11):1315-1327. doi:10.1007/s00109-013-1059-4 
 
32 
Figure Legends 
Figure 1. Cardiac ultrasound confirms the presence of severe PAH and RVH in the 
MCT rat model.  
PAAT, CO, TAPSE and treadmill distance were reduced in MCT vs. PBS rats (A, 
B, F, G). RVFW diastolic thickness and RV/LV+S were increased and RVFW 
thickening was reduced in MCT vs. PBS rats (C, D, E). n > 15/group. MCT, 
monocrotaline. *** P < 0.001 vs. PBS. 
 
Figure 2. MCT rat RV displays microvascular rarefaction. 
(A) Representative confocal microscopic images of RV blood vasculature (green 
color) and the fluorescent intensity over a line of 500 μm. Scale bar = 50 μm; (B) 
Summary of the area intensity of fluorescent signal for albumin−FITC. n = 
7~8/group. MCT, monocrotaline. ** P < 0.01 vs. PBS. 
 
Figure 3. Mdivi-1 and P110 reduce the IR-induced elevation in RVEDP in both 
control and PAH.  
(A, C) Representative traces showing experiments in which two cycles of IR were 
performed in the RV Langendorff model with treatment of vehicle, Mdivi-1 and 
P110. Vehicle control (DMSO or TAT) or treatment (Mdivi-1 or P110) was given 
in the baseline 10 min prior to the first IR challenge. (B, D) Mean±SEM of RVSP 
and RVEDP in PBS and MCT hearts in the Langendorff experiment. RVP at the 
time of 2, 5, 10 and 15 min after reperfusion were compared between groups. IR 
caused an elevation in RVEDP and Midivi-1 or P110 reduced it significantly. n = 
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8~11/group. RVP, RV pressure. MCT, monocrotaline. * P < 0.05 for Mdivi-1 vs. 
vehicle control; # P < 0.05 for P110 vs. vehicle control.  P = 0.05~0.09 for Mdivi-
1 vs. vehicle control at time 65 and 70 min for PBS RVs and at time 40 and 70 
min for MCT RVs.  
 
Figure 4. Both Mdivi-1 and P110 preserve mitochondrial membrane potential in 
both control and PAH RVs with IR.  
           (A) Representative confocal microscopic images of RV tissue stained with 
TMRM. Scale bar = 10 μm; (B) Summary of TMRM intensity. TMRM intensity 
of MCT RVs at baseline (i.e., no IR) was significantly lower than PBS RVs. IR 
caused a decrease in TMRM intensity in PBS RVs but not in MCT RVs. Mdivi-1 
and P110 increased TMRM intensity in both PBS and MCT RVs with IR. n > 
11/group. MCT, monocrotaline. *** P < 0.001 vs. PBS-No IR; # P < 0.05 and ## 
P < 0.01 vs. PBS-IR; $$ P < 0.01 vs. MCT-IR. 
 
Figure 5. Both Mdivi-1 and P110 preserve mitochondrial morphology and 
ultrastructure in both control and PAH RVs with IR.  
(A) Representative TEM images at a magnification of ×13500; (B) Summary of 
mitochondrial area. At baseline without IR, mitochondrial area in MCT RVs was 
significantly greater than that in PBS RVs; IR caused swelling of mitochondria 
and Mdivi-1 or P110 reduced the mitochondrial area in both PBS and MCT RVs 
with IR; (C) Summary of normal mitochondrial percentage. Normal mitochondria 
at baseline without IR were less in MCT vs. PBS RVs; IR decreased the normal 
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mitochondrial percentage and Mdivi-1 or P110 restored it. n > 120 mitochondria 
from 1~2 RV tissues/group. MCT, monocrotaline.  *** P < 0.001 vs. PBS-No IR; 
# P < 0.05 and ### P < 0.001vs. PBS-IR; $ P < 0.05 vs. MCT-IR. 
 
Figure 6. Aconitase activity is reduced in PBS RVs with IR to levels seen in MCT 
RVs at baseline without IR. A reduction but not significant in aconitase activity 
was observed in MCT RVs with IR compared to MCT RVs at baseline without 
IR.  n = 4~6/group. MCT, monocrotaline. * P < 0.05 vs. PBS-No IR. 
 
Figure 7. Both Mdivi-1 and P110 decrease mitochondrial Drp1 expression in both 
control and PAH RVs with IR. Translocation of Drp1 to the mitochondria was 
greater in MCT RVs than in PBS RVs at baseline. Mitochondrial Drp1 expression 
increased in both PBS and MCT RVs following IR. Both Mdivi-1 and P110 
reduced the translocation of Drp1 to the mitochondria though only significantly in 
MCT RVs with IR but not in PBS RV with IR. n = 3~5/group. MCT, 
monocrotaline. * P < 0.05 vs. PBS-No IR; # P < 0.05 vs. MCT-No IR; $ P < 0.05 
vs. MCT-IR. 
 
Figure 8. Proposed mechanistic pathway of Drp1 activation in the RV-IR. Drp1, 
dynamin-related protein 1; Fis1, fission protein 1; ROS, reactive oxygen species.  
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Supplemental Figures 
 
(A) 
  
(B) 
 
Supplemental Figure S1. Comparison of RV pressure between the two vehicle 
controls, i.e., DMSO and TAT. No significant difference in RV pressure was observed 
between DMSO and TAT in either (A) PBS or (B) MCT RVs. RVP, RV pressure; MCT, 
monocrotaline. n = 4~7/group. 
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Supplemental Figure S2. Representative TEM images of mitochondrial morphology 
and ultrastructure at a magnification of ×2100. MCT, monocrotaline; IR, ischemia-
reperfusion. 
 
 
Supplemental Figure S3. Summary of aconitase activity in RV tissues with or without 
treatment of Mdivi-1 or P110 in the Langendorff experiment. No significant change 
was observed with treatment of Mdivi-1 or P110. MCT, monocrotaline; IR, ischemia-
reperfusion. n = 4~6/group. 
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5 
Supplemental Figure S4.  Summary of cytoplasmic Drp1 and mitochondrial pDrp1-
S616 and Fis1 measured from immunoblotting. 
(A) Expression of the inactive, cytoplasmic expression of Drp1 was less though not 
significant in MCT vs. PBS RVs at baseline without IR. IR reduced cytoplasmic Drp1 
expression in normal RVs though not significantly but did not further reduce the low basal 
expression in MCT RVs; Neither Mdivi-1 nor P110 changed the cytoplasmic expression 
of Drp1. n = 3~5/group. (B) Expression of the activated Drp1, i.e., Drp1 phosphorylation 
at serine 616 (pDrp1-616), was increased in mitochondria following IR in PBS RVs. In 
these experiments, the expected increase in mitochondrial pDRp1-616 did not occur in 
MCT RVs with IR (data not shown). n = 2/group.  * P < 0.05 vs. PBS-No IR. (C) 
Mitochondrial expression of Fis1 was not significantly different between PBS and MCT 
RVs. MCT, monocrotaline; IR, ischemia-reperfusion.  n = 3~5/group. 
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Supplemental videos 
 
Videos on RV tissues stained with TMRM (red) and NucBlue (blue) 
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